Repeated dose of prostaglandin E2 vaginal insert when the first dose fails

İlk doz başarısız olduğunda prostaglandin E2 vajinal insertin tekrar kullanımı

Objective: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails.

Materials and Methods: This retrospective study included 1,043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1,000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared.

Results: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006).

Conclusion: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed.

Keywords: Dinoprostone, labor induction, second-dose dinoprostone

Abstract

Address for Correspondence/Yazışma Adresi: Assoc. Prof. Burak Karadağ, Antalya Training and Research Hospital, Clinic of Obstetrics and Gynecology Antalya, Turkey

Phone: +90 242 249 44 00 E-mail: drburakkaradag@gmail.com ORCID ID: orcid.org/0000-0003-2325-4591

Received/Geliş Tarihi: 07.12.2020 Accepted/Kabul Tarihi: 21.02.2021

© Copyright 2021 by Turkish Society of Obstetrics and Gynecology
Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House.
Introduction

Labor induction is widely used for various maternal and fetal indications and is likely to be effective when the cervix is favorable. However, when the cervix is unfavorable (e.g., low Bishop score), iatrogenic cervical ripening is usually employed to increase the probability of vaginal delivery. For this purpose, there are two major options, which include the application of cervical ripening agents such as prostaglandins (PG), and the insertion of mechanical dilators such as cervical ripening balloons. PGs efface the cervix by increasing the water content and dissolving collagen bundles. In addition to these processes, myometrial contraction occurs, an advantage of PG over the use of mechanical dilators, and collectively, these lead to cervical ripening. The efficacy of PGs for cervical ripening and labor induction has been established by randomized trials and recently by a Cochrane review.

Dinoprostone is a prostaglandin E2 (PGE2) analogue and is approved for cervical ripening by the United States Food and Drug Administration. Endocervical gel and vaginal insert forms of dinoprostone are available. The vaginal insert form is approved for use up to 12 and 24 hours in the United States and Europe, respectively. If labor does not ensue, or the expected Bishop change does not occur after administering PG (i.e., the cervix is still unfavorable), there is no consensus as to the preferred methods of labor induction. As a result, there are options such as repeating the PG dose, switching to mechanical dilators, oxytocin induction, or cesarean delivery.

There are insufficient data in the literature regarding the repeated dose of dinoprostone and its safety. Our hypothesis was that repeated PGE2 administration would be associated with poor maternal and fetal outcomes. We aimed to compare the obstetric and neonatal outcomes of pregnant women treated with repeated doses of dinoprostone when the first dose fails.

Materials and Methods

This retrospective study included 1,043 pregnant women treated with dinoprostone for labor induction at Etlik Zübeyde Hanım Women’s Health Training and Research Hospital between November 2012 and August 2015. The protocol used in this study was approved by the Institutional Review Board of Etlik Zübeyde Hanım Women’s Health Training and Research Hospital and performed in accordance with the ethical standards established by the 1964 Declaration of Helsinki. Pregnant women with singleton pregnancies, vertex presentation, a Bishop score ≤6, and normal fetal heart rate tracing were retrospectively reviewed. A previous history of uterine surgery (e.g., cesarean section, myomectomy, septum resection), known fetal anomalies, fetal malpresentation, diagnosis with placenta previa/vasa previa, PG allergy, asthma, abnormal fetal monitoring in the first dose of dinoprostone administration, vaginal delivery contraindication, and estimated fetal weight of 4,000 g or more were excluded from the study. A vaginal insert (Propess®, Ferring, Saint-Prex, Switzerland) with 10 mg slow-release dinoprostone was inserted high in the posterior vaginal fornix for cervical ripening. We recorded the insertion and retrieval times of the dinoprostone vaginal insert. After 24 hours, pregnant women with a Bishop score less than 6 were considered as non-responsive to dinoprostone. Dinoprostone was administered to pregnant women with non-responsive to dinoprostone after 24 hours. Continuous fetal monitoring was performed from the onset of the vaginal insert. Fetal heart rate classification and management were defined according to the American College of Obstetricians and Gynecologists guidelines.

Cervical opening ≥3 cm and active uterine contractions were considered active labor. Dinoprostone was retrieved in cases of active labor, uterine tetanus/tachysystole (more than five contractions in a 10-minute interval), or the presence of abnormal fetal heart monitoring. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1 had a single dose of dinoprostone, and group 2 had a repeated dose. Intrapartum, postpartum, and neonatal outcomes of the groups were compared by reviewing patient files.

Outcome Measures

The primary outcome was vaginal and cesarean section rates. Other outcomes considered were the interval from the start of induction to active labor and delivery, the length of the first stage of labor and the total length of labor, the need for oxytocin augmentation, the occurrence of hyperstimulation, postpartum hemorrhage, and neonatal outcomes.

Statistical Analysis

Patient information was recorded in the Statistical Package for the Social Sciences (SPSS) Version 17.0 program. The distribution of the variables was analyzed using the Kolmogorov-Smirnov test. Continuous variables are expressed as mean ± standard deviation median (range), and categorical variables are expressed as percentages and frequencies. The independent sample t-test was used for comparisons of parametric variables, the Mann-Whitney U for non-parametric variables, and the chi-square test and Fisher’s exact tests for intermittent variables. A value of p<0.05 was considered statistically significant.

Results

Our study included 1,064 pregnant women who underwent dinoprostone induction for labor in the perinatology unit of our hospital between November 2012 and August 2015. Twenty-one pregnant women did not meet the criteria and were excluded from the study. The remaining 1,043 pregnant women were divided into two groups as group 1 (n=1,000), which received only one dose of dinoprostone, and group 2 (n=43), which received a repeated dose. The characteristics of the groups are summarized in Table 1. Age, body mass index (BMI), mean gestational week, number of pregnancies, and amniotic fluid measurements were similar between the two groups.
groups (p>0.05). The most frequent indication for dinoprostone in both groups was post-term pregnancy. The Bishop scores during the first dinoprostone application were similar between the groups (p=0.878), whereas the Bishop score after the first application of dinoprostone was 6 (0-10) in group 1, and 1 (0-4) in group 2 (p=0.001). There was no difference in the need for oxytocin augmentation after dinoprostone retrieval in both groups (p=0.666) (Table 1). Also, 650 (65%) pregnant women in group 1 and 13 (30.2%) in group 2 had vaginal deliveries (p=0.001).

### Table 1. Characteristics and pre and post-Bishop scores of groups and reasons for retrieval of dinoprostone

|                          | Group 1 (single dose) | Group 2 (repeated dose) | p  |
|--------------------------|-----------------------|-------------------------|----|
| **Age (years)**          | 24.4±4.2              | 24.7±4.8                | 0.435 |
| **Parity**               | 0 (0-4)               | 0 (0-1)                 | 0.789 |
| Nulliparous % (n)        | 84.3% (843)           | 93% (40)                | 0.240 |
| **Body mass index (kg/m²)** | 29.1±4.5             | 29.4±5.0                | 0.666 |
| **Gestational age (weeks)** | 39.6±1.7             | 38.7±2.9                | 0.053 |
| Amniotic fluid index % (n) |                       |                         |    |
| Oligohydrannios          | 42.6% (426)           | 41.9% (18)              |    |
| Normal                   | 55.5% (555)           | 58.1% (25)              | 0.617 |
| Polyhydramnios           | 1.9% (19)             | -                       |    |
| Postmaturity (>41 weeks' gestation) | 34.6% (346) | 27.9% (12)              |    |
| FGR                      | 6% (60)               | 16.3% (7)               |    |
| Oligohydrannios          | 25.2% (252)           | 20.9% (9)               |    |
| PROM                     | 2.5% (25)             | 14% (6)                 | 0.001 |
| Hypertension             | 6.7% (66)             | 9.3% (4)                |    |
| Postmaturity + oligohydrannios | 10.9% (109)   | 7% (3)                  |    |
| FGR + oligohydrannios    | 5.2% (52)             | 2.3% (1)                |    |
| Other                    | 8.9% (89)             | 2.3% (1)                |    |
| **Bishop score**         |                       |                         |    |
| At 1st application       | 0 (0-4)               | 0 (0-1)                 | 0.878 |
| at 2nd application       | -                     | 0 (0-4)                 |    |
| at 1st removal           | 6 (0-10)              | 1 (0-4)                 | 0.001 |
| at 2nd removal           | 2 (0-9)               | -                       |    |
| Completed 24 hours       | 10.5% (105)           | 76.7% (33)              |    |
| Active labor             | 64.1% (641)           | -                       |    |
| Uterine tachysystole     | 5.1% (51)             | 18.6% (8)               | 0.001 |
| Non-reassuring fetal status | 7.4% (74)            | -                       |    |
| Spontaneous dislocation  | 5.8% (58)             | 2.3% (1)                |    |
| Other                    | 71.7% (71)            | 2.3% (1)                |    |
| Completed 24 hours       | -                     | 39.5% (17)              |    |
| Active labor             | -                     | 34.9% (15)              |    |
| Reason for 1st retrieval of dinoprostone % (n) |                       |                         |    |
| Uterine tachysystole     | -                     | 4.7% (2)                |    |
| Non-reassuring fetal status | -                   | 14% (6)                 |    |
| Spontaneous dislocation  | -                     | 4.7% (2)                |    |
| Oxytocin augmentation % (n) | 13.6% (136)         | 11.6% (5)               | 0.069 |

*Results are expressed as mean ± standard deviation, **Results are expressed as median (minimum-maximum), PROM: Preterm rupture of membrane, FGR: Fetal growth restriction
The most frequent cesarean indication was non-reassuring fetal status in group 1, and failed induction in group 2. The second stage of delivery time was similar between the two groups (p>0.05). However, latent phase and active phase durations were longer in group 2 (p=0.001, p=0.033, respectively). Ten (1%) women in group 1 and two (4.5%) in group 2 needed postpartum blood transfusions (p=0.031) (Table 2). When neonatal outcomes were evaluated, the mean APGAR score at 1 minute was 8.8±0.5 in group 1 and 8.6±0.7 (p=0.023) in group 2. Furthermore, need for neonatal intensive care unit (NICU) treatment was found in 44 (4.4%) women in group 1 and six (13.6%) women in group 2 (Table 2).

In our study, only one patient in group 1 developed a severe complication (uterine rupture). The cause of dinoprostone retrieval in this patient was active delivery and her uterus ruptured at the second stage of delivery.

### Table 2. Obstetric and neonatal outcomes of groups

|                               | Group 1 (single-dose) (n=1,000) | Group 2 (repeated-dose) (n=43) | p     |
|-------------------------------|---------------------------------|--------------------------------|-------|
| Vaginal delivery % (n)        | 65% (650)                       | 30.2% (13)                      | 0.001 |
| Cesarean indication % (n)     |                                 |                                |       |
| Failed induction              | 11.4% (40)                      | 63.3% (19)                      |       |
| Fetal distress                | 47.4% (166)                     | 23.3% (7)                       |       |
| CPD                           | 34.3% (120)                     | 13.3% (4)                       | 0.001 |
| Cord prolapse                 | 1.1% (4)                        | -                              |       |
| Chorioamnionitis              | 0.6% (2)                        | -                              |       |
| Other                         | 5.2% (18)                       | -                              |       |
| *Time to delivery (hours)     | 16.9±9.12                       | 58.46±16.50                     | 0.001 |
| *Latent phase duration of labor (hours) | 12.67±7.40           | 50.38±12.97                     | 0.001 |
| *Active phase duration of labor (hours) | 4.01±3.74              | 6.26±4.47                       | 0.033 |
| *Second stage duration of labor (min) | 44.99±21.56          | 48.46±15.19                     | 0.564 |
| *Estimated blood loss (mL)    | 179.7±113.2                    | 182±109.2                       | 0.890 |
| Transfusion requirement (+) % (n) | 1% (10)                      | 4.6% (2)                       | 0.031 |
| Number of transfusions (RBC concentrate) | 2 units                  | 80% (8)                       |       |
| % (n)                         | 10% (1)                        | -                             | 0.787 |
| >4 units                      | 10% (1)                        | -                             |       |
| *Birth weight (g)             | 3161.1±484.4                   | 3030±604.2                      | 0.186 |
| *APGAR 1                      | 8.8±0.6                        | 8.6±0.7                        | 0.023 |
| *APGAR 5                      | 9.3±0.5                        | 9.2±0.5                        | 0.081 |
| Need for neonatal intensive care unit % (n) | 4.5% (45)                  | 14% (6)                        | 0.006 |
| Respiratory distress          | 54.5% (24)                     | 100% (6)                       |       |
| Hyperbilirubinemia            | 15.9% (7)                      | -                             | 0.208 |
| Prematurity                   | 11.4% (5)                      | -                             |       |
| Other                         | 18.2% (8)                      | -                             |       |

*Results are expressed as mean ± standard deviation. CPD: Cephalo-pelvic disproportion, RBC: Red blood cell

### Discussion

In this study, we compared the obstetric and neonatal outcomes of pregnant women who underwent labor induction once or twice with dinoprostone. To the best of our knowledge, there is no much information in the literature about the repeated administration of dinoprostone and there are scant data on reliability and efficacy\(^{[7,8,10]}\). Our center is a tertiary teaching hospital and a reference center that has more than 16,000 deliveries annually. Additionally, our hospital is one of the largest centers of the induction of labor in Turkey. The most important finding of this study is the high cesarean rate in repeated dinoprostone administrations for women non-responsive to dinoprostone. Therefore, pregnant women should be informed that the process may result in a cesarean delivery before the second administration and other labor induction methods such as mechanical dilators and oxytocin could be offered.
In our study, most of the pregnant women were nulliparous and the most frequent indication for labor induction was post-maturity. This can be explained by the fact that post-maturity is higher in nulliparous women. On the other hand, the gestational week of women who received dinoprostone for the second time was lower than those given it once, although it was not statistically significant. Probably, the effectiveness of the dinoprostone increases as the gestational week progresses, but more patients are needed to confirm this.

The use of labor induction especially in elective delivery has increased significantly in recent years\(^{(11)}\). Dinoprostone is one of the most commonly used pharmacologic methods for the induction of labor\(^{(12)}\). Cesarean delivery, mechanical dilatation, oxytocin induction, and repeated administration of dinoprostone are alternative methods for non-responsive patients to dinoprostone during labor induction. We use repeated dinoprostone for pregnant women who are non-responsive to single-dose dinoprostone in our center. The success of labor induction depends on many factors such as the general characteristics of the population, age, gestational week, BMI, parity, estimated fetal weight, Bishop score, and labor induction method used\(^{(13-15)}\). In our study, the age, gestational week, BMI, parities of pregnant women were similar between the two groups. Antonazzo et al.\(^{(7)}\) compared the results of patients who received repeated dinoprostone administrations and oxytocin induction in pregnant women who did not respond to dinoprostone. They reported that the cesarean section rate was 44.7% in 47 pregnant women who received repeated dinoprostone administration and 66% in 47 pregnant women who had oxytocin induction. In the literature, the average cesarean delivery rate for labor induction with dinoprostone is 25% (range, 10.5-38.6%), and the vaginal delivery rate within 24 hours is 59.4% (range, 38.2-81.1%) \(^{(16-19)}\). In our study, we observed that the cesarean section rate was 70.5% in 43 pregnant women who received repeated dinoprostone administrations. We speculated that this rate was extremely high, therefore patient selection for repeating dinoprostone should be performed more carefully before the second application.

Additionally, Antonazzo et al.\(^{(7)}\) found no differences in terms of neonatal outcomes (5-minute APGAR score, umbilical artery pH) between the repeated dinoprostone group and the oxytocin group. In our study, the need for NICU treatment and the need for blood transfusion were higher in group 2. Despite of literature\(^{(7)}\), our data showed that repeated administration of dinoprostone is not a safe therapeutic option when first dose fails.

**Study Limitations**

The present study has some limitations such as the relatively small population for repeated dinoprostone group, the absence of other labor induction method groups for patients non-responsive to dinoprostone in labor induction, and its retrospective design. Additional well-designed randomized controlled studies are required to improve our understanding of the efficacy and outcomes (neonatal and maternal) of repeated-dose dinoprostone for women non-responsive to dinoprostone in labor induction.

**Conclusion**

When we evaluated all these obstetric and neonatal data in our study, we observed that dinoprostone administration was associated with an increased rate of cesarean and adverse neonatal outcomes with the second dose compared with single-dose dinoprostone in unresponsive women. As an alternative to applying dinoprostone for the second time, mechanical or other pharmacologic methods should be tried.

**Ethics**

**Ethics Committee Approval:** The protocol used in this study was approved by the Institutional Review Board of Etlik Zübeyde Hanum Women’s Health Training and Research Hospital and performed in accordance with the ethical standards established by the 1964 Declaration of Helsinki.

**Informed Consent:** Retrospective study.

**Peer-review:** Externally and internally peer-reviewed.

**Authorship Contributions**

Concept: C.K., S.E., Design: S.E., E.S.Y., Data Collection or Processing: C.K., T.B., Analysis or Interpretation: Y.A.T., B.K., Literature Search: C.K., Y.A.T., Writing: C.K., B.K.

**Conflict of Interest:** The authors report no conflict of interest.

**Financial Disclosure:** Authors have no financial interests about the research.

**References**

1. Aghideh FK, Mullin PM, Ingles S, Ouzounian JG, Opper N, Wilson ML, et al. A comparison of obstetrical outcomes with labor induction agents used at term. J Matern Fetal Neonatal Med 2014;27:592-6.
2. Rab MT, Mohammed AB, Zahran KA, Hassan MM, Eldeen AR, Ebrahim EM, et al. Transcervical Foley’s catheter versus Cook balloon for cervical ripening in stillbirth with a scarred uterus: a randomized controlled trial. J Matern Fetal Neonatal Med 2015;28:1181-5.
3. Theobald PW, Rath W, Kühne H, Kuhn W. Histological and electron-microscopic examinations of collagenous connective tissue of the non-pregnant cervix, the pregnant cervix, and the pregnant prostaglandin-treated cervix. Arch Gynecol 1982;231:241-5.
4. Keirse MJ. Natural prostaglandins for induction of labor and preinduction cervical ripening. Clin Obstet Gynecol 2006;49:609-26.
5. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2α) for induction of labour at term. Cochrane Database Syst Rev 2014;2014:003101.
6. Chyu JK, Strassner HT. Prostaglandin E2 for cervical ripening: a randomized comparison of Cervidil versus Prepidil. Am J Obstet Gynecol 1997;177:606-11.
7. Antonazzo P, Laoreti A, Personeni C, Grossi E, Martinelli A, Cetin I. Vaginal Dinoprostone Versus Intravenous Oxytocin for Labor Induction in Patients Not Responsive to a First Dose of
8. Macones GA, Hankins GD, Spong CY, Hauth J, Moore T. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008;112:661-6.

9. Petrovic Barbitch M, Gnisci A, Marcelli M, Capelle M, Guidicelli B, Cravello L, et al. Maturation cervicale à terme par utilisation répétée du dispositif intravaginal de dinoprostone [Cervical ripening at term with repeated administration of dinoprostone vaginal pessary]. Gynecol Obstet Fertil 2013;41:346-50.

10. Mohr-Sasson A, Schiff E, Sindel O, Suday RR, Kalter-Farher A, Mashiach R, et al. Second dose of PGE, vaginal insert versus Foley transcervical balloon for induction of labor after failure of cervical ripening with PGE, vaginal insert. J Matern Fetal Neonatal Med 2017;30:2074-7.

11. Sinkey RG, Lacevic J, Reljic T, Hozo I, Gibson KS, Odibo AO, et al. Elective induction of labor at 39 weeks among nulliparous women: The impact on maternal and neonatal risk. PLoS One 2018;13:e0193169.

12. Daykan Y, Biron-Shental T, Navve D, Miller N, Bustan M, Sukenik-Halevy R. Prediction of the efficacy of dinoprostone slow release vaginal insert (Propess) for cervical ripening: A prospective cohort study. J Obstet Gynaecol Res 2018;44:1739-46.

13. Pevzner L, Rayburn WF, Rumney P, Wing DA. Factors predicting successful labor induction with dinoprostone and misoprostol vaginal inserts. Obstet Gynecol 2009;114:261-7.

14. Hirsch L, Borovich A, Gabbay-Benzir V, Maimon-Cohen M, Aviram A, Yoge Y, et al. Can we predict successful cervical ripening with prostaglandin E2 vaginal inserts? Arch Gynecol Obstet 2017;295:343-9.

15. Navve D, Orenstein N, Ribak R, Daykan Y, Shechter-Maor G, Biron-Shental T. Is the Bishop-score significant in predicting the success of labor induction in multiparous women? J Perinatol 2017;37:480-3.

16. Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997;177:612-8.

17. Garry D, Figueroa R, Kalish RB, Catalano CJ, Maulik D. Randomized controlled trial of vaginal misoprostol versus dinoprostone vaginal insert for labor induction. J Matern Fetal Neonatal Med 2003;13:254-9.

18. Özkan S, Caliskan E, Doğer E, Yücesoy I, Özeren S, Vural B. Comparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial. Arch Gynecol Obstet 2009;280:19-24.

19. Triglia MT, Palamara F, Lojacono A, Prefumo F, Frusca T. A randomized controlled trial of 24-hour vaginal dinoprostone pessary compared to gel for induction of labor in term pregnancies with a Bishop score ≤ or = 4. Acta Obstet Gynecol Scand 2010;89:651-7.